A Double-blind, Placebo-controlled Trial of Donepezil Adjunctive Treatment for Cognitive Impairment in Schizophrenia

Central South University

Status and phase

Unknown

Phase 4

Conditions

Schizophrenia

Impaired Cognition

Treatments

Drug: Donepezil

Drug: placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01490567

201002003 (Other Grant/Funding Number)

NSFC30900485

Details and patient eligibility

About

The objective of the study was to study the effects of donepezil on cognition in patients with schizophrenia. The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.

Full description

The investigators conducted a 12-week, double-blind, placebo-controlled trial of donepezil as adjunctive treatment to antipsychotic drugs on patients with schizophrenia.The trial will be complete in 2012.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

DSM-IV diagnosis of schizophrenia as determined by the Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version;
Between 18 and 40 years of age;
Duration of the illness must be longer than 2 year;
Patient's current antipsychotic medication regimen must be stable;
Must be in a stable living arrangement;

Exclusion criteria

Patient has mental retardation or severe organic brain syndromes;
Treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening;
Has suicidal attempts or ideation or violent behavior within the last 12 months;
Patient has a history of alcohol/drug dependence;